Comparative Pharmacology
Head-to-head clinical analysis: ABSTRAL versus DEPODUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSTRAL versus DEPODUR.
ABSTRAL vs DEPODUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Morphine sulfate extended-release liposomal injection; morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The analgesic effects are mediated by activation of mu-opioid receptors in the central nervous system, leading to modulation of pain pathways.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Epidural: 5-15 mg as a single dose (morphine sulfate 10 mg/mL extended-release liposome injection).
None Documented
None Documented
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
The terminal elimination half-life of morphine is approximately 2-4 hours in adults. However, DEPODUR (extended-release liposomal morphine) has a prolonged half-life due to slow release from the liposomal depot, with an effective half-life of about 12-24 hours, supporting once-daily dosing.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Morphine is primarily excreted renally, with approximately 90% of the dose eliminated in urine within 24 hours, mainly as morphine-3-glucuronide (M3G, ~50%), morphine-6-glucuronide (M6G, ~10%), and unchanged morphine (~10%). Fecal excretion accounts for less than 10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic